The purpose of the study is to identify molecular markers at the level of molecular pathway activation to predict efficacy of anti-HER2 therapy with Trastuzumab.
Biopsy and/or surgical samples from Her2-positive breast cancer patients treated with Trastuzumab alone or in combinations with other regimens of chemotherapy with known clinical outcomes will be collected and subjected to mRNA sequencing. Expression profiles will be analysed using original bioinformatic platform Oncobox. Based on comparison of molecular pathways activation strength and clinical response to Trastuzumab and chemotherapy, this study aims to identify molecular markers predicting efficacy of therapy with Trastuzumab and the possibility of further relapse.
Study Type
OBSERVATIONAL
Enrollment
40
Next Generation Sequencing of RNA from tumor samples, rRNA-depleted.
Analysis of RNA-seq data using the Oncobox algorithm.
Standard Trastuzumab treatment regimen recommended for breast cancer
OmicsWay Corp.
Walnut, California, United States
Republican Oncological Dispensary of the Ministry of Healthcare of Karelia Republic
Petrozavodsk, Karelia Republic, Russia
Vitamed LLC
Moscow, Russia
"Oncobox" Ltd.
Moscow, Russia
Tumor response by RECIST v1.1 or pathological response according to Chevallier system
Tumor response by RECIST v1.1 or pathological response according to Chevallier system
Time frame: 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Standard chemotherapy regimen recommended for breast cancer